1. Home
  2. VRNS vs LGND Comparison

VRNS vs LGND Comparison

Compare VRNS & LGND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Varonis Systems Inc.

VRNS

Varonis Systems Inc.

SELL

Current Price

$49.01

Market Cap

5.3B

Sector

Technology

ML Signal

SELL

Logo Ligand Pharmaceuticals Incorporated

LGND

Ligand Pharmaceuticals Incorporated

SELL

Current Price

$302.28

Market Cap

6.2B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
VRNS
LGND
Founded
2004
1987
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.3B
6.2B
IPO Year
2013
1997

Fundamental Metrics

Financial Performance
Metric
VRNS
LGND
Price
$49.01
$302.28
Analyst Decision
Hold
Strong Buy
Analyst Count
22
11
Target Price
$50.14
★ $361.27
AVG Volume (30 Days)
★ 4.0M
177.1K
Earning Date
11-03-2026
10-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 2886.36
EPS
N/A
★ 0.31
Revenue
★ $270,288,000.00
$141,102,000.00
Revenue This Year
$19.05
$8.82
Revenue Next Year
$18.39
$31.67
P/E Ratio
★ N/A
$1,000.90
Revenue Growth
24.35
★ 29.48
52 Week Low
$19.70
$175.89
52 Week High
$50.31
$326.63

Technical Indicators

Market Signals
Indicator
VRNS
LGND
Relative Strength Index (RSI) 55.19 46.71
Support Level $48.71 $280.42
Resistance Level $49.27 $319.83
Average True Range (ATR) 0.21 11.97
MACD -0.07 -1.01
Stochastic Oscillator 56.28 20.53

Price Performance

Historical Comparison
VRNS
LGND

About VRNS Varonis Systems Inc.

Varonis Systems is a cybersecurity vendor focused on data privacy and security. The firm is currently undergoing a cloud transition as it weans its on-premises customers over to its cloud products that are delivered as software-as-a-service. The New York-based firm was founded in 2005 and went public in 2014.

About LGND Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.

Share on Social Networks: